AngTai MicroPrecision Medical Technology (Shanghai) Co., Ltd. has recently declared the successful completion of its Series B funding round, raising hundreds of millions of yuan. This financing endeavor drew interest and investment from both industrial capital and several renowned investment firms, with Chunmu Capital acting as the exclusive financial advisor. The proceeds from this funding will be predominantly channeled into bolstering technological prowess, refining the product ecosystem, expediting the clinical registration process, and fueling an international strategic expansion.

As the inaugural global innovator specializing in a compact, sophisticated surgical robot platform, AngTai MicroPrecision has, since its inception in 2022, effectively broken free from reliance on imported critical technologies. Leveraging its profound technological expertise, the company has constructed a comprehensive innovation chain. Its product range is extensive, encompassing a diverse array of surgical robots and corresponding consumables, with core technologies that are industry-leading and widely acclaimed by clinical practitioners.

Notably, the ophthalmic surgical robot has concluded registered clinical trials and is now on the cusp of market introduction. Additionally, the microscopic robot Kai spans multiple medical fields, showcasing remarkable platform scalability and versatility. The company's founder remarked that this financing not only validates past accomplishments but also underscores confidence in pioneering new surgical techniques and penetrating untapped markets. It also propels the company's entry into the neurosurgical arena.

Chunmu Capital is of the opinion that AngTai MicroPrecision's profound commitment to the high-value surgical robot sector will spearhead industry transformation.